Register entry
Eisai Inc.
- Registered sites
- 6
- Drug products
- 51
- Live patents
- 47
- Countries
- 4
- Base
- United States
Authorisation
Registered operations
What the FDA has registered these sites to do. This is the regulatory record, not a marketing claim.
Analytical testingActive ingredient (API) manufactureLabellingFinished drug manufacturePackaging
Sites
Facilities
6| Site | Location | Operations | FEI |
|---|---|---|---|
| Eisai Manufacturing Ltd | HatfieldUnited Kingdom | Analytical testing, Labelling, Finished drug manufacture, Packaging | 3008356774 |
| Eisai Pharmaceuticals India Private Limited | Anakapalli DistrictIndia | Analytical testing, Active ingredient (API) manufacture, Finished drug manufacture | 3008394488 |
| Eisai Co., Ltd. | GifuJapan | Analytical testing, Finished drug manufacture | 3004967045 |
| Eisai Co., Ltd. | Kamisu-shiJapan | Analytical testing, Active ingredient (API) manufacture | 3002806886 |
| Eisai Inc. | Baltimore, MDUnited States | Analytical testing, Labelling, Finished drug manufacture, Packaging | 1000158705 |
| Eisai Inc. | Raleigh, NCUnited States | Analytical testing | 3012653281 |
Exclusivity
Patents
47Unexpired Orange Book patents where this company is the application holder.
| Product | Active ingredient | Expiry |
|---|---|---|
| ARICEPT | DONEPEZIL HYDROCHLORIDE | Oct 2026 |
| DAYVIGO | LEMBOREXANT | Sept 2031 |
| DAYVIGO | LEMBOREXANT | Oct 2035 |
| HALAVEN | ERIBULIN MESYLATE | Jan 2027 |
| HALAVEN | ERIBULIN MESYLATE | Jul 2027 |
| LENVIMA | LENVATINIB MESYLATE | Sept 2026 |
| LENVIMA | LENVATINIB MESYLATE | Mar 2027 |
| LENVIMA | LENVATINIB MESYLATE | Jul 2027 |
| LENVIMA | LENVATINIB MESYLATE | Jan 2028 |
| LENVIMA | LENVATINIB MESYLATE | Oct 2030 |
| LENVIMA | LENVATINIB MESYLATE | Apr 2031 |
| LENVIMA | LENVATINIB MESYLATE | Aug 2035 |
| LENVIMA | LENVATINIB MESYLATE | Feb 2036 |
| LENVIMA | LENVATINIB MESYLATE | Feb 2036 |
| LENVIMA | LENVATINIB MESYLATE | Mar 2036 |
| LENVIMA | LENVATINIB MESYLATE | Aug 2036 |
| LENVIMA | LENVATINIB MESYLATE | Sept 2036 |
| LENVIMA | LENVATINIB MESYLATE | May 2038 |
| LENVIMA | LENVATINIB MESYLATE | Nov 2038 |
Catalogue
Marketed products
51Showing 51 of 51.
| Brand | Generic name | Form | Category |
|---|---|---|---|
| Aricept | donepezil hydrochloride | TABLET, FILM COATED | NDA |
| Aricept | donepezil hydrochloride | TABLET, FILM COATED | NDA |
| Aricept | donepezil hydrochloride | TABLET, FILM COATED | NDA |
| Banzel | rufinamide | TABLET, FILM COATED | NDA |
| Banzel | rufinamide | TABLET, FILM COATED | NDA |
| Banzel | rufinamide | SUSPENSION | NDA |
| DAYVIGO | lemborexant | TABLET, FILM COATED | NDA |
| DAYVIGO | lemborexant | TABLET, FILM COATED | NDA |
| Fycompa | perampanel | TABLET | NDA |
| Fycompa | perampanel | TABLET | NDA |
| Fycompa | perampanel | TABLET | NDA |
| Fycompa | perampanel | TABLET | NDA |
| Fycompa | perampanel | TABLET | NDA |
| Fycompa | perampanel | TABLET | NDA |
| Fycompa | perampanel | SUSPENSION | NDA |
| Halaven | eribulin mesylate | INJECTION | NDA |
| LECANEMAB AUTOINJECTOR | lecanemab-irmb | INJECTION, SOLUTION | BLA |
| LECANEMAB AUTOINJECTOR | lecanemab-irmb | INJECTION, SOLUTION | BLA |
| LEQEMBI | lecanemab | INJECTION, SOLUTION | BLA |
| LEQEMBI | lecanemab | INJECTION, SOLUTION | BLA |
| - | LORCASERIN HYDROCHLORIDE HEMIHYDRATE, LORCASERIN | TABLET | DRUG FOR FURTHER PROCESSING |
| Lenvima | Lenvatinib | CAPSULE | NDA |
| Lenvima | Lenvatinib | CAPSULE | NDA |
| Lenvima | Lenvatinib | CAPSULE | NDA |
| Lenvima | Lenvatinib | CAPSULE | NDA |
| Lenvima | Lenvatinib | KIT | NDA |
| Lenvima | Lenvatinib | KIT | NDA |
| Lenvima | Lenvatinib | CAPSULE | NDA |
| Lenvima | Lenvatinib | KIT | NDA |
| - | avatrombopag maleate | TABLET, FILM COATED | DRUG FOR FURTHER PROCESSING |
| - | donepezil hydrochloride | TABLET, FILM COATED | DRUG FOR FURTHER PROCESSING |
| - | donepezil hydrochloride | TABLET, FILM COATED | DRUG FOR FURTHER PROCESSING |
| - | donepezil hydrochloride | TABLET, FILM COATED | DRUG FOR FURTHER PROCESSING |
| - | eribulin mesylate | POWDER | BULK INGREDIENT |
| - | eribulin mesylate | POWDER | BULK INGREDIENT |
| - | lemborexant | TABLET, FILM COATED | DRUG FOR FURTHER PROCESSING |
| - | lemborexant | TABLET, FILM COATED | DRUG FOR FURTHER PROCESSING |
| - | lenvatinib | CAPSULE | DRUG FOR FURTHER PROCESSING |
| - | lenvatinib | CAPSULE | DRUG FOR FURTHER PROCESSING |
| - | perampanel | TABLET | DRUG FOR FURTHER PROCESSING |
| - | perampanel | TABLET | DRUG FOR FURTHER PROCESSING |
| - | perampanel | TABLET | DRUG FOR FURTHER PROCESSING |
| - | perampanel | TABLET | DRUG FOR FURTHER PROCESSING |
| - | perampanel | TABLET | DRUG FOR FURTHER PROCESSING |
| - | perampanel | TABLET | DRUG FOR FURTHER PROCESSING |
| - | perampanel | TABLET | DRUG FOR FURTHER PROCESSING |
| - | perampanel | TABLET | DRUG FOR FURTHER PROCESSING |
| - | perampanel | TABLET | DRUG FOR FURTHER PROCESSING |
| - | perampanel | TABLET | DRUG FOR FURTHER PROCESSING |
| - | perampanel | TABLET | DRUG FOR FURTHER PROCESSING |
| - | perampanel | TABLET | DRUG FOR FURTHER PROCESSING |
Provenance
Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.